Given the success of the first edition of
Double-Edged Swords: Important Factors Connecting Metabolic Disorders and Cancer Development - From Basic Research to Translational Applications and the continuing advances in the field, we are pleased to announce the Volume II.
The relationship between metabolic dysfunctions and cancer development has been continuously evolving, informed by research efforts in the fields of epidemiology, endocrinology, cancer biology, chemistry, genomics, metabolomics among others. Metabolism and cancer can intersect at the physiological level, where metabolic disorders and cancer malignancies occur as comorbid or mutually-promoting conditions; or at the molecular level, where metabolic alterations regulate tumorigenesis and oncogenic/tumor-suppressive pathways govern the onset of metabolic syndromes.
The increasingly complex spider web connecting metabolic dysfunctions and cancer development reveals both distinctive and shared mechanisms underlying different disease indications. It also points to unique opportunities, either through repurposing existing tools or discovering new strategies, to develop targeted therapies against a wide variety of metabolic and cancerous diseases. In our previous Research Topic:
Double-edged Swords: Genetic Factors That Influence The Pathogenesis of Both Metabolic Disease and Cancer , we highlighted ten genetic factors/mechanisms that influence the pathogenesis of both metabolic disease and cancer. The attention it generated to date ( >110,000 article views, >22,000 article downloads, >500 citations) signals a fast-growing interest from scientific communities of different disciplines. We aim to highlight more recent advances to inform a diverse audience working on basic and translational research.
We are welcoming contributions (Original Research, Review, Mini-Review, Methods, Perspective, Case Report–etc.) highlighting (but not limited to) the following subjects:
1. Updated knowledge of metabolism- and tumorigenesis-regulating mechanisms in the progression of specific disease indications.
2. Genetic/Molecular/Environmental factors that bridge pathogenic mechanisms between metabolic disease and cancer.
3. Unique methodologies (Proteogenomic, metabolomic, computational, chemical biology–etc.) to identify critical factors linking metabolic dysfunction and cancer biology.
4. Novel therapeutic strategies tailored to target vulnerabilities linking metabolic abnormalities and pro/anti-tumorigenic pathways.
5. Provocative innovations and hypotheses, rooted in existing scientific evidence, designed to reduce disease burden of metabolic disorder and cancer.